HOME >> BIOLOGY >> NEWS
West-Eberhard elected to the Italian Accademia Nazionale dei Lincei

Galileo Gallilei's and the oldest academy of science in the world. In 1603, four young men put their names to a document about the pursuit of science, and in so doing brought into being the Accademia Nazionale dei Lincei. Galileo Galilei added his great name and fame to the Accademia in 1611, and the number of members increased steadily with the addition of foreign and Italian men of science, poets, lawyers, and philologists until in 1625 the number of fellows reached 32. Currently, the aim of the Accademia Nazionale dei Lincei is to promote, coordinate, integrate and spread scientific knowledge in its highest expression, in the unity and universality of culture.

A newly elected foreign member, Mary Jane West-Eberhard, biologist at the Smithsonian Tropical Research Institute (STRI) joins the oldest academy of science in the world, and the most important cultural and scientific society of Italy. The Academy is divided into two Classes: Physical, Mathematical and Natural Sciences and Moral, Historical and Philological Sciences. Each of the two Classes comprises 90 national members, 90 corresponding members and 90 foreign members, 27 of them in the biological sciences.

West-Eberhard, whose primary research is on the behavior and evolution of social wasps, is the author of the book Developmental plasticity and evolution, published by Oxford University Press in 2003, and recipient of the R. R. Hawkins Award of the American Association of Publishers for the "Outstanding Professional, Reference or Scholarly Work of 2003." One reviewer called the book "an intellectual blitzkrieg" whose "scope and scholarship are truly awe inspiring."

Soon after the publication of Developmental plasticity and evolution, the American Society of Naturalists presented West-Eberhard with the 2003 Sewall Wright Award, sometimes called "the ultimate recognition for an established evolutionary biologist" created in 1991 in honor of evolutionary biologist Sewall Wright.
'"/>

Contact: Mary Jane West-Eberhard
mjwe@sent.com
506-228-0001
Smithsonian Tropical Research Institute
10-Aug-2005


Page: 1 2

Related biology news :

1. Candidate research sites selected for the National Ecological Observatory Network
2. Depiction of findings selected as 2007 Image of the Year by Society for Nuclear Medicine
3. CSHL selected for odENCODE Data Coordination Center
4. University of Arizona neurobiologist John Hildebrand elected to the National Academy of Sciences
5. Einsteins Dr. Vern Schramm elected to the National Academy of Sciences
6. 5 Stanford professors elected to National Academy of Sciences
7. Salk scientist Ursula Bellugi elected to National Academy of Sciences
8. Psychology professor elected to American Academy of Arts and Sciences
9. ORNLs Thundat elected fellow of AAAS
10. Leading scientists elected to EMBO ranks
11. Three UCSF faculty elected to Institute of Medicine

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: West Eberhard elected the Italian Accademia Nazionale dei Lincei

(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
(Date:3/30/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , announced today that ... the Company,s application to conduct a Phase 2 global ... for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... 30, 2015    Intrexon Corporation (NYSE: ... and Merck Serono, the biopharmaceutical business of Merck ... announced an exclusive strategic collaboration and license agreement ... (CAR-T) cancer therapies. This collaboration advances Merck Serono,s ... modulate the immune system,s natural ability to fight ...
(Date:3/30/2015)... and BELLINGHAM, Washington, USA (PRWEB) March 29, 2015 ... in Europe and the United States and plenary talks ... planned for SPIE Optics + Optoelectronics next ... over 700 technical presentations in 17 conferences alongside a ... for optics and photonics , the event will run ...
(Date:3/30/2015)... 30, 2015  Naldemedine, an investigational peripherally acting ... & Co., Ltd., met its primary and secondary ... for the treatment of opioid-induced constipation (OIC) in ... therapy. Study results showed that naldemedine (0.2 mg ... frequency of spontaneous bowel movement (SBM) compared with ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
Cached News: